Yoda Therapeutics has dosed the first patient in a Phase 2 trial of YA-101, an AI-pioneered novel chemical entity designed to treat Multiple System Atrophy (MSA) by inhibiting neuroinflammation and enhancing neural plasticity.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.